BCAL Diagnostics Limited (AU:BDX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BCAL Diagnostics Limited has achieved a significant milestone with the accreditation of its North Ryde laboratory by the National Association of Testing Authorities Australia (NATA). This accreditation paves the way for the commercial launch of their innovative breast cancer detection test, BREASTEST, in partnership with Sydney Breast Clinic. The advancement underscores BCAL’s commitment to providing high-quality breast cancer screening solutions, enhancing early detection and intervention opportunities.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.